7 completed. 7 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 7 |
| Phase 2 | 2 | Completed 2 |
Follow DLBCL: new trials by email Literature Review of DLBCL trials Research Report on DLBCL
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies Cyclophosphamide, Fludarabine, ACE1831 - B-cell Lymphoma, Non Hodgkin Lymphoma | Phase 1 | Completed | Acepodia Biotech, Inc. | 16 | 2023-01-21 | 2026-06-30 |
| Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHL KT-413 - Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma | Phase 1 | Completed | Kymera Therapeutics, Inc. | 7 | 2022-06-13 | 2024-12-10 |
| A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors CYT-0851, CYT-0851 in combination with gemcitabine, CYT-0851 in combination with capecitabine - Malignancy, Non-hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | Cyteir Therapeutics, Inc. | 169 | 2019-10-09 | 2024-12-24 |
| Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies Fludarabine, Cyclophosphamide, CD22 CAR - B-ALL, B-cell Non Hodgkin Lymphoma | Phase 1 | Completed | Matthew Frank | 52 | 2019-09-12 | 2026-03-30 |
| Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study) AZD9150, Acalabrutinib, AZD6738 - NHL, DLBCL | Phase 1 | Completed | Acerta Pharma BV | 30 | 2018-06-19 | 2022-08-15 |
| Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers IONIS-STAT3Rx - Advanced Cancers, DLBCL | Phase 1 / Phase 2 | Completed | Ionis Pharmaceuticals, Inc. | 64 | 2012-02-27 | 2018-06-25 |
| A Double-blind, Randomized Controlled Study in CD20-positive Diffuse B Cell Non-Hodgkin's Lymphoma Subjects TL011, Rituximab - DLBCL | Phase 1 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 186 | 2010-09-01 | 2013-10-22 |
Lymphoma, Non-Hodgkin (4) · Lymphoma, B-Cell (2) · Lymphoma, Follicular (2) · Lymphoma, Large B-Cell, Diffuse (2) · Breast Neoplasms (1) · Burkitt Lymphoma (1) · Head and Neck Neoplasms (1) · Lymphoma (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Mantle-Cell (1) · Multiple Myeloma (1) · Neoplasms (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1) · Sarcoma (1)
Hemic and Lymphatic Diseases (6) · Immune System Diseases (6) · Immunoproliferative Disorders (6) · Lymphatic Diseases (6) · Lymphoproliferative Disorders (6) · Neoplasms by Histologic Type (6) · Lymphoma (5) · Neoplasms (5) · Lymphoma, B-Cell (2) · Adnexal Diseases (1) · Blood Protein Disorders (1) · Breast Diseases (1) · Bronchial Neoplasms (1) · Carcinoma (1) · Carcinoma, Bronchogenic (1)
Rituximab (3) · Cyclophosphamide (2) · fludarabine (2) · AZD5153 (1) · Bendamustine Hydrochloride (1) · Capecitabine (1) · Gemcitabine (1) · MZ1 compound (1) · acalabrutinib (1) · ceralasertib (1) · danvatirsen (1) · magrolimab (1) · obinutuzumab (1)
Acepodia Biotech, Inc. (1) · Acerta Pharma BV (1) · Cyteir Therapeutics, Inc. (1) · Ionis Pharmaceuticals, Inc. (1) · Kymera Therapeutics, Inc. (1) · Matthew Frank (1) · Teva Branded Pharmaceutical Products R&D, Inc. (1)
United States (6) · United Kingdom (2) · Bulgaria (1) · Estonia (1) · France (1) · Hong Kong (1) · Hungary (1) · Italy (1) · Latvia (1) · Poland (1) · Russia (1) · Spain (1) · Taiwan (1) · Ukraine (1)
Ashwin Gollerkeri, MD (1) · Ian Flinn, MD, PhD (1) · Mariano Provencio, MD, PhD (1) · Markus Renschler, MD (1) · Matthew Frank, MD, PhD (1) · Steve Hughes, MD (1)
PMID 30446007, PMID 33512414, PMID 38996463
2017 (1), K08CA248968 (1)